Multiple sclerosis Trials in Caen, France
Conditions / Multiple sclerosis / Caen, France
Research into Multiple sclerosis spans multiple therapeutic approaches and trial phases.
31 total trials for this combination
Showing top 10 of 31 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01797965 | Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 | TERMINATED | PHASE3 |
| NCT03369665 | Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS) | COMPLETED | PHASE4 |
| NCT04548999 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01480076 | Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis | COMPLETED | PHASE4 |
| NCT00629642 | Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis | COMPLETED | PHASE4 |
| NCT01480063 | An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice | COMPLETED | — |
| NCT01817166 | Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome | COMPLETED | PHASE3 |
| NCT05269004 | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING | — |
| NCT05630547 | A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis | TERMINATED | PHASE2 |
| NCT01895335 | Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients | COMPLETED | PHASE4 |